ArticleAnalytical chemistry2026
Affinity-Activated Protein Switches for Modular and Signal-ON Detection of Small Molecules.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Protein switches offer powerful strategies for detecting small molecules, yet current designs often suffer from limited dynamic range, lack of reversible control, and poor adaptability to nonfluorescent platforms. Here, we report a semisynthetic affinity-activated protein switch strategy that enables Signal-ON detection of small molecules across diverse environments, including live cells, Drosophila brain, and lateral flow assays. The switch consists of a self-labeling protein fused to a sensing protein and a synthetic probe containing a small-molecule ligand, a sterically shielded N'-3 urea nitrogen biotin derivative (N3B), and a tagging moiety. Ligand binding induces a conformational change that exposes the N3B for streptavidin-based signal output. This design achieves high dynamic range (up to 142-fold), low background, and nanomolar sensitivity for detecting sulfonamide, while demonstrating the transferability of the platform to trimethoprim detection. Reversible switching is enabled by the reduced N3B-streptavidin affinity, allowing signal reset via competitive displacement. In Drosophila brain, the protein switch enables spatially resolved ex vivo imaging of drug exposure. Furthermore, conjugation to gold nanoparticles allows robust Signal-ON colorimetric detection on lateral flow test strips. This work establishes a generalizable framework for building programmable protein switches with tunable output modes and potential diagnostic applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.